title: Association between survivin -31G > C promoter polymorphism and cancer risk: a meta-analysis.
abstract: Survivin is an inhibitor of apoptosis protein and has a crucial role in the development of cancer. The survivin -31G>C (rs9904341) promoter polymorphism influences survivin expression and has been implicated in cancer risk. However, conflicting results have been published from studies on the association between survivin -31G>C polymorphism and the risk of cancer. To clarify the role of this polymorphism in cancer, we performed a meta-analysis of all available and relevant published studies, involving a total of 3485 cancer patients and 3964 control subjects. Odds ratios (ORs) and 95% confidence intervals (CIs) were used to assess the strength of the associations. The overall results indicated that the variant genotypes were associated with a significantly increased cancer risk (CC vs GG: OR=1.58, 95% CI=1.20-2.10; CC/GC vs GG: OR=1.23, 95% CI=1.00-1.51; CC vs GG/GC: OR=1.51, 95% CI=1.23-1.85). In the stratified analyses, significantly increased risk was associated with the Asian populations (CC vs GG: OR=1.67, 95% CI=1.16-2.40; CC vs GG/GC: OR=1.50, 95% CI=1.17-1.91). We also performed the analyses by cancer type, and no statistical association was observed. The results suggest that the survivin -31G>C promoter polymorphism might be associated with an increased risk of cancer, especially in the Asian populations.
authors.affiliation: Department of Neurosurgery, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu Province, PR China.
authors.forename: Xiefeng
authors.initials: X
authors.lastname: Wang
authors.forename: Lili
authors.initials: L
authors.lastname: Huang
authors.forename: Yanjie
authors.initials: Y
authors.lastname: Xu
authors.forename: Zhumei
authors.initials: Z
authors.lastname: Shi
authors.forename: Yingyi
authors.initials: Y
authors.lastname: Wang
authors.forename: Junxia
authors.initials: J
authors.lastname: Zhang
authors.forename: Xirui
authors.initials: X
authors.lastname: Wang
authors.forename: Lei
authors.initials: L
authors.lastname: Cao
authors.forename: Hui
authors.initials: H
authors.lastname: Luo
authors.forename: Jiawei
authors.initials: J
authors.lastname: Chen
authors.forename: Ning
authors.initials: N
authors.lastname: Liu
authors.forename: Yongmei
authors.initials: Y
authors.lastname: Yin
authors.forename: Yongping
authors.initials: Y
authors.lastname: You
mesh_terms: D000483:Alleles; D044466:Asian People / Q000235:genetics; D016022:Case-Control Studies; D016001:Confidence Intervals; D005006:Ethnicity / Q000235:genetics; D005787:Gene Frequency; D018740:Genetic Heterogeneity; D005838:Genotype; D006801:Humans; D051034:Inhibitor of Apoptosis Proteins / Q000235:genetics*; D009369:Neoplasms / Q000208:ethnology / Q000235:genetics*; D016017:Odds Ratio; D011110:Polymorphism, Genetic; D011401:Promoter Regions, Genetic; D012307:Risk Factors; D012680:Sensitivity and Specificity; D000077022:Survivin
chemical_list: C107489:BIRC5 protein, human; D051034:Inhibitor of Apoptosis Proteins; D000077022:Survivin